Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 2608 participants.

Also called NCT02618577

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 2,608 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02618577
  • EudraCT 2015-003997-33
Other papers using this trial's data
  • Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes The New England journal of medicine, 2023-09-28 DOI, PubMed 37622677

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Austria, Belgium, Bulgaria, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Spain, Sweden, Ukraine, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02618577. Randomized; double masking; primary purpose prevention. Start 2016-02 (actual); primary completion 2022-12-31 (actual). Results posted on 2025-02-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes
Acronym
NOAH
Condition
Atrial High Rate Episodes
Intervention (Drug)
Edoxaban
Intervention (Drug)
ASA
Lead sponsor
Atrial Fibrillation Network (class: other)
Collaborator
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (class: industry)
Collaborator
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) (class: other)

Record details

Record id
cardio:ct-nct02618577
Content hash
33469252e9b1150d54fe0b16bbecda7d627ab11c9cba9fabf7638655f1a33bb5